Brokerages Set Dyne Therapeutics, Inc. (NYSE:DYN) Price Target at $27.20
Dyne Therapeutics, Inc. (NYSE:DYN – Get Free Report) has received a consensus rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price […]
More Stories
Advisors Asset Management Inc. Makes New Investment in Cencora, Inc. (NYSE:COR)
Advisors Asset Management Inc. bought a new stake in Cencora, Inc. (NYSE:COR – Free Report) during the 1st quarter, according...
Hydro One (TSE:H) Hits New 1-Year High at $42.03
Shares of Hydro One Limited (TSE:H – Get Free Report) reached a new 52-week high on Wednesday . The company...
Advisors Asset Management Inc. Increases Stock Holdings in Herc Holdings Inc. (NYSE:HRI)
Advisors Asset Management Inc. lifted its position in Herc Holdings Inc. (NYSE:HRI – Free Report) by 9.2% in the first...
Advisors Asset Management Inc. Decreases Position in Principal Financial Group, Inc. (NYSE:PFG)
Advisors Asset Management Inc. lowered its stake in shares of Principal Financial Group, Inc. (NYSE:PFG – Free Report) by 12.2%...
Shell Asset Management Co. Buys 7,728 Shares of General Motors (NYSE:GM)
Shell Asset Management Co. lifted its position in General Motors (NYSE:GM – Free Report) (TSE:GMM.U) by 27.5% during the first...
Emergent BioSolutions (NYSE:EBS) Reaches New 52-Week High at $13.23
Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) reached a new 52-week high on Wednesday . The company...